Principal Financial Group’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Principal Financial Group’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,768	Closed	-$1.12M	–	2225
2015 Q2	$1.12M	Buy	1,768 +158	+10%	+$84K	﹤0.01%	1771
2015 Q1	$828K	Buy	1,610 +10	+0.6%	+$5.04K	﹤0.01%	1792
2014 Q4	$857K	Sell	1,600 -135	-8%	-$60.8K	﹤0.01%	1817
2014 Q3	$2.6M	Buy	1,735 +93	+6%	+$135K	﹤0.01%	1589
2014 Q2	$2.25M	Sell	1,642 -75	-4%	-$87K	﹤0.01%	1659
2014 Q1	$2.38M	Sell	1,717 -131	-7%	-$152K	﹤0.01%	1617
2013 Q4	$1.84M	Buy	1,848 +6	+0.3%	+$6.2K	﹤0.01%	1683
2013 Q3	$1.92M	Buy	1,842 +1,482	+412%	+$1.58M	﹤0.01%	1632
2013 Q2	$394K	Buy	+360	New	+$401K	﹤0.01%	1875

Other funds holding VIRX

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Principal Financial Group's VIRX Position: Q3 2015 in Review

Principal Financial Group sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2015, closing a stake of 1,768 shares — an estimated $1.12M sold.

Principal Financial Group first reported a position in VIRX in Q2 2013 and held it in 9 quarters. The position peaked at $2.6M in Q3 2014. 59 funds tracked by Wall St. Rank hold VIRX as of Q3 2015.

Principal Financial Group reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
Principal Financial Group sold 1,768 Viracta Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $1.12M.
Principal Financial Group first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 9 quarters.
Principal Financial Group's Viracta Therapeutics, Inc. Common Stock position peaked at $2.6M in Q3 2014.
59 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2015.

Based on Principal Financial Group's 13F filing for Q3 2015, filed 9 Nov 2015.